Effects of clopidogrel on the platelet activation response in horses.

The research article investigates the effects of clopidogrel on platelet activation in horses. The study, which involved testing on 12 healthy adult mares, used various methodologies to compare the platelet activation response before and after the administration of clopidogrel.

Study Design and Methodology

• The research was a masked study and involved a total of 12 healthy adult mares. The horses were randomly divided into two groups, one of which was administered a placebo, while the other group received clopidogrel. The clopidogrel was given via a nasogastric tube, starting with an initial dose of 4 mg/kg, followed by a maintenance dose of 2mg/kg every 24 hours.
• Blood samples were collected and tested before the treatment began and 72 hours after it started. The tests were conducted to measure platelet response to ADP and collagen stimulation, the effect on coagulation, and various other aspects of platelet function and activation.

Main Results

• The main results showed that treatment with clopidogrel led to a significant decrease in the aggregation response of the platelets to 5 μM and 10 μM ADP stimuli. However, it was observed that some horses (two in the study) demonstrated resistance to the inhibitory effects of clopidogrel on platelets.
• All other platelet function tests did not indicate any significant differences after clopidogrel treatment. These results indicate that the antiplatelet action of clopidogrel in horses was primarily detected by the ADP-induced light transmission aggregometry test.

Conclusions

• From this study, it appears that clopidogrel’s impact on reducing platelet activation is variable among horses. This mirrors observations in humans, suggesting a similar interindividual variability to clopidogrel treatment among horses.
• The study suggests that the potential clinical efficacy of clopidogrel as an antiplatelet drug in horses may be influenced by this variability, as some individuals may show resistance to the drug’s inhibitory effects on platelets.

The research offers valuable insights, especially for veterinary medicine, by shedding light on the specific effects of clopidogrel on horses’ platelet function and highlighting the potential for variability in response to the drug. Further investigation can build on this work to better understand and address this variability in response to clopidogrel treatment among horses.